Cerep Grants BioPrint® Access to AstraZeneca
News May 12, 2006
Through this alliance, AstraZeneca will have non-exclusive access to physicochemical, pharmacological and clinical data on BioPrint® compounds as well as to BioPrint® informatics tools to support internal drug discovery and development.
Payment of the license fee has been recognized upon acceptance of the data and IT tools delivered by Cerep in the first quarter 2006.
"We are very happy to announce this alliance with AstraZeneca," commented Mark Crawford, Executive Vice President for Cerep.
"BioPrint® has been established in the industry as an extremely useful tool to support drug discovery and drug development."
"We are particularly proud to have the value of BioPrint® recognized by AstraZeneca."
"We believe that database-supported pharmaco-informatics can play an important role in expediting drug discovery. We have been pleased with Cerep's BioPrint® database and we look forward to implementing this tool at AstraZeneca," commented Tim Hammond, Vice President of Safety Assessment UK, for AstraZeneca.
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE